drugset / Trial / NCT05347147
A Trial to Determine the Efficacy and Safety of Presendin in IIH
Phase 3
Terminated
14 enrolled
Invex Therapeutics Ltd.
Premier Research · collabUniversity Hospital Birmingham · collabUniversity of Iowa · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Idiopathic intracranial hypertension (IIH) has significant associated morbidity and reduced quality of life. There is a significant risk of visual loss and patients also typically suffer with chronic disabling headaches. This trial has been designed to evaluate the efficacy and safety of a new formulation of exenatide (Presendin) in the reduction of intracranial pressure (ICP) in patients with IIH.
Timeline
- Start
- 2022-11-18
- Primary completion
- 2023-09-18
- Completion
- 2023-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 2 mg | Subcutaneous |